Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies
Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.
Published in European urology (01.02.2023)
Published in European urology (01.02.2023)
Get full text
Journal Article
A0532 - Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies
Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.
Published in European urology (01.02.2023)
Published in European urology (01.02.2023)
Get full text
Journal Article
556TiP A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001)
Lakhani, N.J., Braña, I., Chiu, V.K., Dowlati, A., Lee, E.K., McGoldrick, S.M., Minchom, A., Tian, X., Patnaik, A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Rathkopf, D., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N.J., Hawley, J., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K., Emamekhoo, H., Reichert, Z., Nguyen, H., Wells, A., Kandimalla, R., Suryawanshi, S., Wu, J., Arora, V., Pourdehnad, M., Armstrong, A.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
Mckean, M., Weise, A.M., Papadopoulos, K.P., Crown, J.P., Thomas, S.S., Mehnert, J.M., Kaczmar, J., Kim, K.B., Lakhani, N.J., Yushak, M.L., Mani, J., Fang, F., Brennan, L., Lowy, I., Salvati, M.E., Fury, M.G., Lewis, K., Hamid, O.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Hamid, O., Weise, A., Kim, T.M., Mckean, M.A., Lakhani, N.J., Kaczmar, J., Papadopoulos, K.P., Chen, S., Mani, J., Jankovic, V., Kroog, G., Sims, T., Lowy, I., Gullo, G.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Ray-Coquard, I.L., Liu, J.F., O'Malley, D., Oaknin, A., Pothuri, B., Lorusso, D., Eskander, R.N., Westin, S., Lakhani, N.J., McKean, W.B., Koyama, T., Kitano, S., Lim, M.C., Gomez-Roca, C.A., Perez Fidalgo, J.A., Curigliano, G., Campone, M., Sharkey, B., Avsar, E., Friedman, C.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
Oaknin, A., Drescher, C., Banda, K., Duska, L., Ribrag, V., Tewari, A., Lakhani, N.J., Eberst, L., Harvey, R.D., Sanchez, L.M. Manso, Lorusso, D., Kindler, H., Walter, H.S., Illescas, D.G., Pons-Tostivint, E., Thakur, A.G., Kann, L., Reddy, A., Faulhaber, N., González-Martín, A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors
Melero, I., Lakhani, N.J., Powderly, J., Adjei, A.A., Lopez, J.S., Paz-Ares, L.G., Moreno Candilejo, I., Thistlethwaite, F., Rohrberg, K.S., Jerusalem, G., Malmberg, A., Ioan-Facsinay, A., Upadhyay, P.J., Tan, B., Bartz, R., Gaziel, T.B.B., Forssmann, U., Celik, I., Gann, C., De Mattos-Arruda, L.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors
Scott, A., Call, J.A., Chandana, S., Borazanci, E., Falchook, G.S., Bordoni, R., Richey, S., Starodub, A., Chung, V., Lakhani, N.J., Lam, E., Schaffer, K., Wang, J.S., Shapiro, G., Sachdev, J.C., Beaupre, D., Tolcher, A.W.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Mckean, M.A., Lakhani, N.J., Arkenau, H-T., Symeonides, S., Evans, T.R.J., Lim, E.A., Fontana, E., Bupathi, M., Mclaren, A., Chandana, S.R., Ding, T-E., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Bexon, A., Falchook, G.S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
Garralda, E., Sukari, A., Lakhani, N.J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., Palcza, J., Jha, S., Chaney, M., Abraham, A.K., Healy, J., Falchook, G.S.
Published in ESMO open (01.12.2022)
Published in ESMO open (01.12.2022)
Get full text
Journal Article
OA12 A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor
Wu, Y., Lakhani, N.J., Boyer, M., Zhou, Q., Rasco, D.W., Huang, Y., Men, L., Li, Y., Xia, Z., Wang, H., Ji, J., Lu, B., He, Z., Dong, Q., Yang, D., Zhai, Y.
Published in Journal of thoracic oncology (01.12.2018)
Published in Journal of thoracic oncology (01.12.2018)
Get full text
Journal Article
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.
Published in ESMO open (01.08.2022)
Published in ESMO open (01.08.2022)
Get full text
Journal Article
A-305 - A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma
Kaczmar, J., Papadopoulos, K., Ansstas, G., Birnbaum, A., Mehnert, J., Hamid, O., Hughes, B., Rabinowits, G., Wei, A., Yushak, M., Mani, J., Fang, F., Wang, J., Kroog, G., Salvati, M., Lowy, I., Fury, M., Lakhani, N.J.
Published in EJC skin cancer (2024)
Published in EJC skin cancer (2024)
Get full text
Journal Article
A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma
Kaczmar, J., Papadopoulos, K., Ansstas, G., Birnbaum, A., Mehnert, J., Hamid, O., Hughes, B., Rabinowits, G., Wei, A., Yushak, M., Mani, J., Fang, F., Wang, J., Kroog, G., Salvati, M., Lowy, I., Fury, M., Lakhani, N.J.
Published in EJC skin cancer (2024)
Published in EJC skin cancer (2024)
Get full text
Journal Article